Ram Kumar Singh

About

Ram Kumar Singh, Postdoctoral Fellow
Lymphoma and Myeloma Department
MD Anderson Cancer Centre
Houston, Texas, USA
Phone: +1 8328885099
Email: [email protected]

Educational Qualifications
1. Postdoctoral Fellow, M D Anderson Cancer Centre, Houston, Texas, USA [2017-Till date]
2. Ph.D. in Life Science, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai, Maharashtra, India [2010-2016]
3. Masters in Life Science, Devi Ahilya University, Indore, India: Distinction [2007-2009]

Achievements and Awards:
1. Young Investigator award at International Myeloma Workshop, Boston, USA, 2019
2. Best poster award during an international conference on new ideas in cancer-challenging dogmas, 2016.
3. Received an international travel grant from TMH, HBNI and Patel charitable trust, Mumbai, India for oral presentation at cancer therapy conference, Brisbane, Australia, 2015.
4. Awarded CSIR-UGC Senior Research Fellowship (SRF) from August 2012-2016
5. Awarded CSIR-UGC Junior Research Fellowship (JRF) from August 2010-August 2012
6. Qualified Graduate Aptitude Test (GATE) conducted by HRDG Govt. of India (2010).
7. Awarded Shyama Devi Jaiswal memorial award for scoring 1st rank in B.Sc. entrance examination (2005)
8. Reviewer for Nature Journal, Scientific Reports
Personal Details:
Date of Birth: 7th February 1984
Gender: Male
Nationality: Indian
Marital Status: Married
Languages Known: English, Hindi and Marathi

Employment

• University of Texas MD Anderson Cancer Center Postdoctoral Fellow
  2017 - Present

Education

• Advanced Centre for Treatment Research and Education in Cancer PhD.
  2010 - 2016

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• Activating KRAS , NRAS , and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
  Proceedings of the National Academy of Sciences 2020 DOI: 10.1073/pnas.2005052117
  +Save
• Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma
  Blood 2019 DOI: 10.1182/blood-2018-06-859686
  +Save
• HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p
  Blood 2018 DOI: 10.1182/blood-2018-99-118412
  +Save
• Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
  Leukemia 2018 DOI: 10.1038/s41375-018-0044-x
  +Save
• Targeting nucleolin for better survival in diffuse large B-cell lymphoma
  Leukemia 2017 DOI: 10.1038/leu.2017.215
  +Save
• Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells
  The International Journal of Biochemistry & Cell Biology 2015 DOI: 10.1016/j.biocel.2015.02.001
  +Save
• IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells
  Cancer Letters 2014 DOI: 10.1016/j.canlet.2014.08.023
  +Save
• Stem Cells: The Holy Grail of Regenerative Medicine
  Engineering in Translational Medicine 2013 DOI: 10.1007/978-1-4471-4372-7_2
  +Save
• An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression
  Cell 2012 DOI: 10.1016/j.cell.2012.11.054
  +Save